Included in the formulation
АТХ:A.11.D Vitamin B1 and its combination with vitamins B6 and B12
Pharmacodynamics:The agent regulating metabolic processes in the central nervous system is a synthetic compound that is close in structure to thiamine (has an open thiazole cycle, additional disulfide bond and lipophilic ether). Has high efficiency in symptomatic treatment of patients with functional asthenic conditions.
Pharmacokinetics:Absorption from the gastrointestinal tract is high, Cmax is determined 1-2 hours after administration. The half-life is about 5 hours. It is excreted by the kidneys. It is readily soluble in fats, easily penetrates the BBB. Unlike thiamine, it is able to accumulate in the cells of the reticular formation, the hippocampus and the dentate gyrus, as well as the Purkinje cells and the glomeruli of the granular layer of the cerebellar cortex.
Indications:Asthenic conditions in hypo- and avitaminosis, long-term illnesses, after surgical interventions.
IV.E50-E64.E63 Other types of malnutrition
V.F40-F48.F48.0 Neurasthenia
Contraindications:Hypersensitivity, children's age; pregnancy, breast-feeding.
Carefully:Persons under 18 years of age should not be prescribed because of a lack of clinical data.
Pregnancy and lactation:Information on the effect on pregnancy and fetus is absent. There is no information on the penetration into breast milk. It is not recommended to prescribe during pregnancy and during breastfeeding.
The category of FDA recommendations is not defined.
Dosing and Administration:Inside, the daily dose is 400-600 mg, the duration of the course of treatment is set individually.
Side effects:Allergic reactions; Excitement (in the elderly).
Overdose:Symptoms (excitation with the phenomena of euphoria and tremor of extremities) are transient in nature and do not require special treatment.
Interaction:Not described.
Special instructions:A synthetic compound close in structure to thiamine: has an open thiazole ring, an additional disulfide bond, and a lipophilic ester. Insufficiently studied drug.
In patients with a large depressive episode (DSM III-R) sulbutiamine did not have antidepressant effect when administered at a dose of 600 mg for 8 weeks. The drug contributed to the resolution of psycho-behavioral inhibition that occurs with a major depressive episode, thereby facilitating the social, professional and family rehabilitation of patients.